Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
X. Cynthia(Washington University in St. Louis), Helen Piwnica‐Worms(Centre for Cancer Biology)
Cited by 222
Related Papers
The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01
|Journal of Biological Chemistry|2000|541
Kinetics of regulated protein–protein interactions revealed with firefly luciferase complementation imaging in cells and living animals
|Proceedings of the National Academy of Sciences|2004|443
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
|Journal of Clinical Oncology|2017|411
Contribution of p53 to Metastasis
|Cancer Discovery|2014|368